tmcao

Pramipexole (SND 919) is a selective dopamine receptor agonist used in the therapy of Parkinson disease. Pramipexole therapy is associated with a low rate of transient serum enzyme elevations during treatment but has not been implicated in cases of clinically apparent acute liver injury.

Pramipexole dihydrochloride hydrate (Mirapex) is the hydrochloride salt of pramipexole, a benzothiazole derivative. As a nonergot dopamine agonist, pramipexole binds to D2 and D3 dopamine receptors in the striatum and substantia nigra of the brain.

Neuroprotective agent 6 (Compound Y12) functions as an antioxidant and displays prominent neuroprotective effects in both oxygen-glucose deprivation/reperfusion (OGD/R) induced cell models and transient middle cerebral artery occlusion (tMCAO) induced animal models. Additionally, this compound shows significant metal chelating activity towards Cu2+.

RIPK1-IN-33 is an orally active RIPK1 inhibitor with excellent blood-brain barrier permeability, exhibiting an IC50 of 0.115 μM. It demonstrates significant anti-ferroptosis activity, radical scavenging capability (IC50= 123.3 μM), and anti-lipid peroxidation effects (IC50= 9.72 μM). In transient middle cerebral artery occlusion (tMCAO) models, it significantly reduces cerebral infarct volume and improves neurological scores. RIPK1-IN-33 is suitable for ischemic stroke research.

TRPM2-IN-2 is a potent and selective TRPM2 inhibitor (IC50= 0.66 μM) with minimal activity against TRPM8 and TRPV1 (IC50> 10 μM). It demonstrates significant neuroprotective effects in both an in vitro oxygen-glucose deprivation/reperfusion (OGD/R) model and an in vivo transient middle cerebral artery occlusion (tMCAO) mouse model. TRPM2-IN-2 can be used for research related to ischemic stroke.

L-Palmitoylcarnitine chloride (Palmitoyl-L-carnitine chloride) is a fatty acid metabolite with antithrombotic properties that protects mice from ischemic stroke by counteracting intracerebral thrombosis in the tMCAO model.L-Palmitoylcarnitine chloride (Palmitoyl-L-carnitine chloride) is a fatty acid metabolite with antithrombotic properties. Palmitoylcarnitine chloride inhibits the Na/K pump in the heart and inhibits FeCl 3-induced arterial thrombosis Attenuates intracerebral thrombosis and inflammation in a mouse model of transient middle cerebral artery occlusion (tMCAO).

LFHP-1c is a novel PGAM5 inhibitor that shows neuroprotective activity in an ischemic stroke model, preventing BBB destruction after transient middle cerebral artery occlusion (tMCAO) in rats.LFHP-1c can be used to study cerebral ischemic stroke.

Palmitoyl L-Carnitine-d3 Hydrochloride is a deuterated derivative of Palmitoyl L-carnitine. Palmitoyl L-carnitine is a long-chain acylcarnitine formed from palmitic acid and carnitine, playing a pivotal role in mitochondrial fatty acidβ-oxidation and energy metabolism. Under pathological conditions such as myocardial ischemia, it accumulates within cell membranes. Research indicates that it alters the membrane lipid environment and modulates KATP channels, thereby affecting the electrophysiological properties of myocytes. As a deuterated internal standard, this compound is primarily utilized in mass spectrometry-based (LC-MS/MS) quantitative analysis, leveraging the kinetic isotope effect (KIE) to enhance precision in pharmacokinetic studies.

PSD-95/nNOS PPI-IN-1 is an inhibitor targeting the interaction between PSD-95 and nNOS, potentially crossing the blood-brain barrier. It binds with high affinity to the PSD-95 PDZ2 domain (Ki= 19.45 μM). By reducing intracellular ROS levels and inhibiting apoptosis, it counteracts glutamate-induced excitotoxicity. In rat tMCAO models, PSD-95/nNOS PPI-IN-1 significantly decreases brain infarct volume. This compound is useful for research in acute ischemic stroke.